Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034

Primary Biliary Cholangitis Market 2025 – By Treatment Type (Drugs, Liver Transplantation),By Diagnosis (Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses), By End User (Hospitals, Specialty Clinics, Homecare, Other End-Users), And By Region, Opportunities And Strategies – Global Forecast To 2035

Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034

Report Price : $4490.00 $3367.00 | Pages : 319 | Published : May 2025 | Delivery Time: Immediately Info icon | Format : pdf icon

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Regional Data
Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034
Description Table Of Contents Tables & Figures

Market Insights

Related Reports

Primary Biliary Cholangitis Market Definition

Primary biliary cholangitis (PBC) is a chronic, progressive liver disease that primarily affects the bile ducts within the liver. It is an autoimmune condition in which the body’s immune system mistakenly attacks the small bile ducts, leading to inflammation and scarring. Over time, this damage impairs bile flow, causing a buildup of toxic substances that can lead to liver fibrosis, cirrhosis and ultimately liver failure.

The primary biliary cholangitis market consists of sales by entities (organizations, sole traders and partnerships) of primary biliary cholangitis drugs and treatments that are used to treat PBC. PBC predominantly affects middle-aged women, though it can also occur in men. It is typically diagnosed in individuals between the ages of 40 and 60, often following routine blood tests that indicate liver abnormalities.

Primary Biliary Cholangitis Market Size and growth rate 2025 to 2029: Graph

Primary Biliary Cholangitis Market Size

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019. The market is expected to grow from $979.47 million in 2024 to $1,499.06 million in 2029 at a rate of 8.88%. The market is then expected to grow at a CAGR of 8.73% from 2029 and reach $2,277.60 million in 2034.

Growth in the historic period resulted from the increase in smoking, rising demand for personalized medicine, increase in liver transplantation awareness and increasing awareness and early diagnosis. Factors that negatively affected growth in the historic period was regulatory hurdles.

Going forward, the increasing healthcare expenditure, growing geriatric population, surge in liver cancer and favorable government support will drive the growth. Factor that could hinder the growth of the primary biliary cholangitis market in the future include inadequate response to first-line treatment.  

Primary Biliary Cholangitis Market Drivers

The key drivers of the primary biliary cholangitis market include:

Increasing Healthcare Expenditure

During the forecast period, the increasing healthcare expenditure is expected to propel the growth of the primary biliary cholangitis market. Higher healthcare spending drives pharmaceutical innovation, enhancing treatments and clinical research for primary biliary cholangitis. Increased budgets improve insurance coverage and reimbursement, making advanced therapies more accessible. Expanded healthcare infrastructure, including specialized centers and diagnostics, enables early detection and treatment, boosting patient adoption rates. For instance, according to the economic forecast from the office for budget responsibility (OBR) and treasury, planned health spending in the UK is expected to rise to £192 billion ($244.43 billion) in 2024/25 from £182 billion ($231.70 billion) in 2022/23.  Additionally, according to national health expenditures accounts (NHEA) by KFF, a US-based independent source for health policy research, polling and journalism, health spending in the USA is expected to rise by 5% from 2023 to 2024, reaching $4.9 trillion.  Therefore, the increasing healthcare expenditure will drive the growth of the primary biliary cholangitis market.

Primary Biliary Cholangitis Market Restraints

The key restraints on the primary biliary cholangitis market include:

Inadequate Response To First-Line Treatment

The inadequate response to first-line treatment is expected to hinder the growth of the primary biliary cholangitis market during the forecast period. Patients unresponsive to UDCA may need second-line therapies like obeticholic acid (OCA) or fibrates. However, high costs, side effects and insurance limitations can hinder adoption, restricting market expansion. Without accessible and effective alternatives, market growth may face significant obstacles, limiting overall demand and slowing industry progress. For instance, in December 2024, according to study published in the journal scientific reports, the ursodeoxycholic acid (UDCA) is the primary treatment for primary biliary cholangitis (PBC), however, it is not effective for all patients. Research suggests that up to 40% of individuals with primary biliary cholangitis exhibit an inadequate response to UDCA therapy.  Therefore, the inadequate response to first-line treatment will restrain the growth of the primary biliary cholangitis market.

Primary Biliary Cholangitis Market Trends

Major trends shaping the primary biliary cholangitis market include:

Role Of Combination Therapy In Liver Disease Management

Major companies operating in the primary biliary cholangitis market are focusing on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care. Combination therapy refers to the use of two or more treatments or drugs together to target a specific condition, enhancing the overall therapeutic effect.  For example, in June 2024, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company received U.S. Food and Drug Administration (FDA) approval for Ipsen's Iqirvo (elafibranor) 80 mg (miligram) tablets for treating primary biliary cholangitis (PBC). This drug is a first-in-class PPAR (peroxisome proliferator-activated receptor) treatment. It is intended for use in combination with ursodeoxycholic acid (UDCA) for adults who do not respond adequately to UDCA, or as a monotherapy for patients who cannot tolerate UDCA.

Advancements In Bile Acid Analog-Based Therapies

Major companies operating in the primary biliary cholangitis market are focused on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC). This combination aims to provide a more effective approach to managing PBC while securing market exclusivity. By integrating OCA, a bile acid analog, with bezafibrate, a PPAR (Peroxisome Proliferator-Activated Receptors) agonist, these treatments have the potential to improve patient outcomes and quality of life. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the OCA-bezafibrate combination as a potential therapy for PBC, a progressive liver disease. Additionally, obeticholic acid, marketed as Ocaliva, is already approved for PBC treatment in the US.

Opportunities And Recommendations In The Primary Biliary Cholangitis Market

Opportunities – The top opportunities in the primary biliary cholangitis market segmented by treatment type will arise in the drugs segment, which will gain $511.63 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by diagnosis will arise in the liver tests segment, which will gain $139.56 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by end user will arise in the hospitals segment, which will gain $247.45 million of global annual sales by 2029. The primary biliary cholangitis market size will gain the most in the USA at $130.97 million.

Recommendations- To take advantage of the opportunities, The Business Research Company recommends the primary biliary cholangitis companies to focus on combination therapy to improve treatment outcomes, focus on orphan drug development using OCA-bezafibrate combinations, focus on drug development to drive market growth, focus on liver tests to maximize diagnostic market growth, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for drug development and commercialization, provide competitively priced offerings, continue to use B2B promotions and focus on specialty clinics to capture high-growth end-user demand.

chesta image

Book your 30 minutes free consultation with our research experts

Contact Us

Primary Biliary Cholangitis Market Segmentation

The primary biliary cholangitis market is segmented by treatment type, by diagnosis and by end user.



By Treatment Type –


The primary biliary cholangitis market is segmented by treatment type into:

    • a) Drugs

    • b) Liver Transplantation

The drugs market was the largest segment of the primary biliary cholangitis market segmented by treatment type, accounting for 96.32% or $943.47 million of the total in 2024. Going forward, the drugs segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by treatment type, at a CAGR of 9.05% during 2024-2029.



By Diagnosis –


The primary biliary cholangitis market is segmented by diagnosis into:

    • a) Magnetic Resonance Elastography (MRE)

    • b) Magnetic Resonance Cholangiopancreatography (MRCP)

    • c) Ultrasound

    • d) Fibroscan

    • e) Cholesterol Test

    • f) Antibody Tests

    • g) Liver Tests

    • h) Other Diagnoses

The liver tests market was the largest segment of the primary biliary cholangitis market segmented by diagnosis, accounting for 21.02% or $205.87 million of the total in 2024. Going forward, the liver tests segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by diagnosis, at a CAGR of 10.91% during 2024-2029.



By End User –


The primary biliary cholangitis market is segmented by end user into:

    • a) Hospitals

    • b) Specialty Clinics

    • c) Homecare

    • d) Other End Users

The hospitals market was the largest segment of the primary biliary cholangitis market segmented by end user, accounting for 47.22% or $462.53 million of the total in 2024. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the primary biliary cholangitis market segmented by end user, at a CAGR of 10.36% during 2024-2029.



By Geography - The primary biliary cholangitis market is segmented by geography into:

      o Asia Pacific

      • • China

      • • India

      • • Japan

      • • Australia

      • • Indonesia

      • • South Korea

      o North America

      • • USA

      • • Canada

      o South America

      • • Brazil

      o Western Europe

      • • France

      • • Germany

      • • UK

      • • Italy

      • • Spain

      o Eastern Europe

      • • Russia

      o Middle East

      o Africa

North America was the largest region in the primary biliary cholangitis market, accounting for 37.46% or $366.89 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the primary biliary cholangitis market will be Asia Pacific and South America where growth will be at CAGRs of 11.54% and 10.80% respectively. These will be followed by Western Europe and Africa where the markets are expected to grow at CAGRs of 8.61% and 7.98% respectively.

Primary Biliary Cholangitis Market Competitive Landscape

Major Competitors are:

  • Intercept Pharmaceuticals Inc.

  • Mayo Clinic Laboratories

  • University of Pittsburgh Medical Center (UPMC)

  • Stanford Health Care

  • Duke University Hospital

    • Other Competitors Include:

  • UCLA Medical Center

  • King's College Hospital

  • NewYork-Presbyterian Hospital

  • Cleveland Clinic

  • Johns Hopkins Hospital

  • Gannex Pharma Co., Ltd.

  • Gilead Sciences

  • Intercept Pharmaceuticals

  • Shenzhen Hepalink Pharmaceutical Co., Ltd.  

  • Chia Tai Tianqing Pharmaceutical

  • Zhongshan Pharm

  • Lupin Limited

  • Jadeite Medicines

  • Ipsen SA

  • Mitsubishi Tanabe Pharma

  • Astellas Pharma

  • Takeda Pharmaceutical

  • Hanmi Pharmaceutical

  • Yuhan Corporation

  • Ipsen Global

  • COUR Pharmaceuticals

  • Abbott Laboratories

  • Cadila Pharmaceuticals

  • Mylan N.V.  

  • F. Hoffmann-La Roche Ltd

  • Teva Pharmaceutical Industries Ltd

  • GlaxoSmithKline plc

  • Novartis AG

  • AbbVie

  • Hikma Pharmaceuticals PLC

  • Bayer AG

  • Boehringer Ingelheim International GmbH

  • Genfit S.A.  

  • Alfasigma S.p.A.  

  • Calliditas Therapeutics AB

  • Glenmark Pharmaceuticals

  • ICE Pharma  

  • Umecrine Cognition AB  

  • Merck Co

  • AstraZeneca

  • Sanofi S.A.  

  • Bristol-Myers Squibb  

  • Mirum Pharmaceuticals Inc.  

  • NGM Biopharmaceuticals Inc.

  • Fiocruz

  • Drag Pharma

  • Dipharma

  • Clínica Alemana

  • Pfizer Brasil

  • Glaxosmithkline Brasil

  • Novartis Argentina S.A.  

  • Merck Chile

  • AION Labs

  • EVA Pharma

  • Gensenta

  • Eczacibasi Group

  • Biond Biologics

  • Diurnal Group

  • Er-Kim

  • Birgi Mefar Group

  • Escient Pharmaceuticals

  • TARGET PharmaSolutions Inc.  

  • HighTide Biopharma Inc.  

  • CymaBay Therapeutics Inc.
    • Author : Abhilash Pyata

      Table Of Contents

      1 Executive Summary

      1.1 Primary Biliary Cholangitis – Market Attractiveness And Macro Economic Landscape

      2 Table Of Contents

      3 List Of Tables

      4 List Of Figures

      5 Report Structure

      6 Market Characteristics

      6.1 General Market Definition

      6.2 Summary

      6.3 Primary Biliary Cholangitis Market Definition And Segmentations

      6.4 Market Segmentation By Treatment Type

      6.4.1 Drugs

      6.4.2 Liver Transplantation

      6.5 Market Segmentation By Diagnosis

      6.5.1 Magnetic Resonance Elastography (MRE)

      6.5.2 Magnetic Resonance Cholangiopancreatography (MRCP)

      6.5.3 Ultrasound

      6.5.4 Fibroscan

      6.5.5 Cholesterol Test

      6.5.6 Antibody Tests

      6.5.7 Liver Tests

      6.5.8 Other Diagnoses

      6.6 Market Segmentation By End User

      6.6.1 Hospitals

      6.6.2 Specialty Clinics

      6.6.3 Homecare

      6.6.4 Other End-Users

      7 Major Market Trends

      7.1 Role Of Combination Therapy In Liver Disease Management

      7.2 Advancements In Bile Acid Analog-Based Therapies

      7.3 Strategic Partnerships Driving Innovation In PBC Treatment

      8 Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

      8.1 Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

      8.1.1 Political

      8.1.2 Economic

      8.1.3 Social

      8.1.4 Technological

      8.1.5 Environmental

      8.1.6 Legal

      8.2 Analysis Of End Use Industries

      8.2.1 Hospitals And Specialty Clinics

      8.2.2 Homecare

      8.2.3 Diagnostic Laboratories

      8.2.4 Pharmaceutical & Biotechnology Companies

      8.2.5 Other End Users

      8.3 Global Primary Biliary Cholangitis Market Growth Rate Analysis

      8.4 Historic Market Growth, 2019 – 2024, Value ($ Million)

      8.4.1 Market Drivers 2019 – 2024

      8.4.2 Market Restraints 2019 – 2024

      8.5 Forecast Market Growth, 2024 – 2029, 2034F Value ($ Million)

      8.5.1 Market Drivers 2024 – 2029

      8.5.2 Market Restraints 2024 – 2029

      8.6 Forecast Growth Contributors/Factors

      8.6.1 Quantitative Growth Contributors

      8.6.2 Drivers

      8.6.3 Restraints

      8.7 Global Primary Biliary Cholangitis Total Addressable Market (TAM)

      9 Global Primary Biliary Cholangitis Market Segmentation

      9.1 Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.2 Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.3 Global Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.4 Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      9.5 Global Primary Biliary Cholangitis Market, Sub-Segmentation By Liver Transplantation, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      10 Primary Biliary Cholangitis Market, Regional and Country Analysis

      10.1 Global Primary Biliary Cholangitis Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      10.2 Global Primary Biliary Cholangitis Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11 Asia-Pacific Market

      11.1 Summary

      11.2 Market Overview

      11.2.1 Region Information

      11.2.2 Market Information

      11.2.3 Background Information

      11.2.4 Government Initiatives

      11.2.5 Regulations

      11.2.6 Regulatory Bodies

      11.2.7 Major Associations

      11.2.8 Taxes Levied

      11.2.9 Corporate Tax Structure

      11.2.10 Investments

      11.2.11 Major Companies

      11.3 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.4 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.5 Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.6 Asia-Pacific Primary Biliary Cholangitis Market: Country Analysis

      11.7 China Market

      11.8 Summary

      11.9 Market Overview

      11.9.1 Country Information

      11.9.2 Market Information

      11.9.3 Background Information

      11.9.4 Government Initiatives

      11.9.5 Regulations

      11.9.6 Regulatory Bodies

      11.9.7 Major Associations

      11.9.8 Taxes Levied

      11.9.9 Corporate Tax Structure

      11.9.10 Investments

      11.9.11 Major Companies

      11.10 China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.11 China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.12 China Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.13 India Market

      11.14 India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.15 India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.16 India Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.17 Japan Market

      11.18 Summary

      11.19 Market Overview

      11.19.1 Country Information

      11.19.2 Market Information

      11.19.3 Background Information

      11.19.4 Government Initiatives

      11.19.5 Regulations

      11.19.6 Regulatory Bodies

      11.19.7 Major Associations

      11.19.8 Taxes Levied

      11.19.9 Corporate Tax Structure

      11.19.10 Major Companies

      11.20 Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.21 Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.22 Japan Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.23 Australia Market

      11.24 Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.25 Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.26 Australia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.27 Indonesia Market

      11.28 Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.29 Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.30 Indonesia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.31 South Korea Market

      11.32 Summary

      11.33 Market Overview

      11.33.1 Country Information

      11.33.2 Market Information

      11.33.3 Background Information

      11.33.4 Government Initiatives

      11.33.5 Regulations

      11.33.6 Regulatory Bodies

      11.33.7 Major Associations

      11.33.8 Taxes Levied

      11.33.9 Corporate Tax Structure

      11.33.10 Major Companies

      11.34 South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.35 South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      11.36 South Korea Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12 Western Europe Market

      12.1 Summary

      12.2 Market Overview

      12.2.1 Region Information

      12.2.2 Market Information

      12.2.3 Background Information

      12.2.4 Government Initiatives

      12.2.5 Regulations

      12.2.6 Regulatory Bodies

      12.2.7 Major Associations

      12.2.8 Taxes Levied

      12.2.9 Corporate tax structure

      12.2.10 Investments

      12.2.11 Major Companies

      12.3 Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.4 Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.5 Western Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.6 Western Europe Primary Biliary Cholangitis Market: Country Analysis

      12.7 UK Market

      12.8 UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.9 UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.10 UK Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.11 Germany Market

      12.12 Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.13 Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.14 Germany Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.15 France Market

      12.16 France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.17 France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.18 France Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.19 Italy Market

      12.20 Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.21 Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.22 Italy Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.23 Spain Market

      12.24 Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.25 Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      12.26 Spain Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13 Eastern Europe Market

      13.1 Summary

      13.2 Market Overview

      13.2.1 Region Information

      13.2.2 Market Information

      13.2.3 Background Information

      13.2.4 Government Initiatives

      13.2.5 Regulations

      13.2.6 Regulatory Bodies

      13.2.7 Major Associations

      13.2.8 Taxes Levied

      13.2.9 Corporate Tax Structure

      13.2.10 Major companies

      13.3 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.4 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.5 Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.6 Eastern Europe Primary Biliary Cholangitis Market: Country Analysis

      13.7 Russia Market

      13.8 Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.9 Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      13.10 Russia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14 North America Market

      14.1 Summary

      14.2 Market Overview

      14.2.1 Region Information

      14.2.2 Market Information

      14.2.3 Background Information

      14.2.4 Government Initiatives

      14.2.5 Regulations

      14.2.6 Regulatory Bodies

      14.2.7 Major Associations

      14.2.8 Taxes Levied

      14.2.9 Corporate Tax Structure

      14.2.10 Investments

      14.2.11 Major Companies

      14.3 North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.4 North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.5 North America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.6 North America Primary Biliary Cholangitis Market: Country Analysis

      14.7 USA Market

      14.8 Summary

      14.9 Market Overview

      14.9.1 Country Information

      14.9.2 Market Information

      14.9.3 Background Information

      14.9.4 Government Initiatives

      14.9.5 Regulations

      14.9.6 Regulatory Bodies

      14.9.7 Major Associations

      14.9.8 Taxes Levied

      14.9.9 Corporate Tax Structure

      14.9.10 Investments

      14.9.11 Major Companies

      14.10 USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.11 USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.12 USA Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.13 Canada Market

      14.14 Summary

      14.15 Market Overview

      14.15.1 Country Information

      14.15.2 Market Information

      14.15.3 Background Information

      14.15.4 Government Initiatives

      14.15.5 Regulations

      14.15.6 Regulatory Bodies

      14.15.7 Major Associations

      14.15.8 Taxes Levied

      14.15.9 Corporate Tax Structure

      14.15.10 Major Companies

      14.16 Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.17 Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      14.18 Canada Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15 South America Market

      15.1 Summary

      15.2 Market Overview

      15.2.1 Region Information

      15.2.2 Market Information

      15.2.3 Background Information

      15.2.4 Government Initiatives

      15.2.5 Regulations

      15.2.6 Regulatory Bodies

      15.2.7 Major Associations

      15.2.8 Taxes Levied

      15.2.9 Corporate Tax Structure

      15.2.10 Investments

      15.2.11 Major Companies

      15.3 South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.4 South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.5 South America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.6 South America Primary Biliary Cholangitis Market: Country Analysis

      15.7 Brazil Market

      15.8 Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.9 Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      15.10 Brazil Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16 Middle East Market

      16.1 Summary

      16.2 Market Overview

      16.2.1 Region Information

      16.2.2 Market Information

      16.2.3 Background Information

      16.2.4 Government Initiatives

      16.2.5 Regulations

      16.2.6 Regulatory Bodies

      16.2.7 Major Associations

      16.2.8 Taxes Levied

      16.2.9 Corporate Tax Structure

      16.2.10 Major Companies

      16.3 Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16.4 Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      16.5 Middle East Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17 Africa Market

      17.1 Summary

      17.2 Market Overview

      17.2.1 Region Information

      17.2.2 Market Information

      17.2.3 Background Information

      17.2.4 Government Initiatives

      17.2.5 Regulations

      17.2.6 Regulatory Bodies

      17.2.7 Major Associations

      17.2.8 Taxes Levied

      17.2.9 Corporate Tax Structure

      17.2.10 Major Companies

      17.3 Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17.4 Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      17.5 Africa Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, Value ($ Million)

      18 Competitive Landscape and Company Profiles

      18.1 Company Profiles

      18.2 Intercept Pharmaceuticals Inc.

      18.2.1 Company Overview

      18.2.2 Products And Services

      18.2.3 Business Strategy

      18.2.4 Financial Overview

      18.3 Mayo Clinic Laboratories

      18.3.1 Company Overview

      18.3.2 Products And Services

      18.3.3 Business Strategy

      18.3.4 Financial Overview

      18.4 University of Pittsburgh Medical Center (UPMC)

      18.4.1 Company Overview

      18.4.2 Products And Services

      18.4.3 Financial Overview

      18.5 Stanford Health Care

      18.5.1 Company Overview

      18.5.2 Products And Services

      18.5.3 Financial Overview

      18.6 Duke University Hospital

      18.6.1 Company Overview

      18.6.2 Products And Services

      18.6.3 Financial Overview

      19 Other Major And Innovative Companies

      19.1 UCLA Medical Center

      19.1.1 Company Overview

      19.1.2 Products and Services

      19.2 King’s College Hospital

      19.2.1 Company Overview

      19.2.2 Products and Services

      19.3 NewYork-Presbyterian Hospital

      19.3.1 Company Overview

      19.3.2 Products and Services

      19.4 Cleveland Clinic

      19.4.1 Company Overview

      19.4.2 Products and Services

      19.5 Johns Hopkins Hospital

      19.5.1 Company Overview

      19.5.2 Products and Services

      19.6 GENFIT S.A

      19.6.1 Company Overview

      19.6.2 Products and Services

      19.7 Ipsen Pharma SA

      19.7.1 Company Overview

      19.7.2 Products and Services

      19.8 Gilead Sciences Inc.

      19.8.1 Company Overview

      19.8.2 Products and Services

      19.9 Ascletis Pharma Inc.

      19.9.1 Company Overview

      19.9.2 Products and Services

      19.10 Calliditas Therapeutics AB

      19.10.1 Company Overview

      19.10.2 Products and Services

      19.11 Cour Pharmaceutical

      19.11.1 Company Overview

      19.11.2 Products and Services

      19.12 GlaxoSmithKline plc (GSK)

      19.12.1 Company Overview

      19.12.2 Products and Services

      19.13 HighTide Biopharma Inc.

      19.13.1 Company Overview

      19.13.2 Products and Services

      19.14 Mirum Pharmaceuticals Inc.

      19.14.1 Company Overview

      19.14.2 Products and Services

      19.15 NGM Biopharmaceuticals Inc.

      19.15.1 Company Overview

      19.15.2 Products and Services

      20 Competitive Benchmarking

      21 Competitive Dashboard

      22 Key Mergers And Acquisitions

      22.1 Gilead Sciences Acquired CymaBay Therapeutics

      22.2 Alfasigma Acquired Intercept Pharmaceuticals

      22.3 Ipsen Acquired Albireo Pharma

      22.4 Advanz Pharma Corp. Limited Acquired Intercept Pharmaceuticals

      23 Recent Development In Primary Biliary Cholangitis Market

      23.1 Orphan Drug Designation To CNP-104 For Primary Biliary Cholangitis

      23.2 FDA Grants Accelerated Approval To Seladelpar For Primary Biliary Cholangitis

      24 Opportunities And Strategies

      24.1 Global Primary Biliary Cholangitis Market In 2029 – Countries Offering Most New Opportunities

      24.2 Global Primary Biliary Cholangitis Market In 2029 – Segments Offering Most New Opportunities

      24.3 Global Primary Biliary Cholangitis Market In 2029 – Growth Strategies

      24.3.1 Market Trend Based Strategies

      24.3.2 Competitor Strategies

      25 Primary Biliary Cholangitis Market, Conclusions And Recommendations

      25.1 Conclusions

      25.2 Recommendations

      25.2.1 Product

      25.2.2 Place

      25.2.3 Price

      25.2.4 Promotion

      25.2.5 People

      26 Appendix

      26.1 Geographies Covered

      26.2 Market Data Sources

      26.3 Research Methodology

      26.4 Currencies

      26.5 The Business Research Company

      26.6 Copyright and Disclaimer

    List Of Tables

      Table 1: Global Primary Biliary Cholangitis Market, Historic, 2019 – 2024, $ Million
    • Table 2: Global Primary Biliary Cholangitis Market, Forecast, 2024 – 2029, 2034F , $ Million
    • Table 3: Global Self-Service Coffee Machine Market TAM, 2024 And 2034, $ Million
    • Table 4: Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 5: Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 6: Global Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 7: Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 8: Global Primary Biliary Cholangitis Market, Sub-Segmentation By Liver Transplantation, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 9: Global Primary Biliary Cholangitis Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 10: Global Primary Biliary Cholangitis Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 11: Asia-Pacific GDP Per Capita, By Country, 2019-2024, $
    • Table 12:  Asia-Pacific Population, By Country, 2019-2029, Millions
    • Table 13: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 14: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 15: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 16: China GDP Per Capita, 2019-2024, $
    • Table 17:  China Population, 2019-2029, Millions
    • Table 18: China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 19: China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 20: China Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 21: India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 22: India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 23: India Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 24: Japan GDP Per Capita, By Country, 2019-2024, $
    • Table 25:  Japan Population, By Country, 2019-2029, Millions
    • Table 26: Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 27: Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 28: Japan Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 29: Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 30: Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 31: Australia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 32: Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 33: Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 34: Indonesia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 35: South Korea GDP Per Capita, 2018-2023, $
    • Table 36:  South Korea Population, 2018-2028, Millions
    • Table 37: South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 38: South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 39: South Korea Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 40: Western Europe GDP Per Capita, By Country, 2019-2024, $
    • Table 41:  Western Europe Population, By Country, 2019-2029, Millions
    • Table 42: Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 43: Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 44: Western Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 45: UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 46: UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 47: UK Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 48: Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 49: Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 50: Germany Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 51: France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 52: France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 53: France Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 54: Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 55: Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 56: Italy Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 57: Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 58: Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 59: Spain Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 60: Eastern Europe GDP Per Capita, By Country, 2019-2024, $
    • Table 61:  Eastern Europe Population, By Country, 2019-2029, Millions
    • Table 62: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 63: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 64: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 65: Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 66: Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 67: Russia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 68: North America GDP Per Capita, By Country, 2019-2024, $
    • Table 69:  North America Population, By Country, 2019-2029, Millions
    • Table 70: North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 71: North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 72: North America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 73: USA GDP Per Capita, 2019-2024, $
    • Table 74:  USA Population, 2019-2029, Millions
    • Table 75: USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 76: USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 77: USA Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 78:Canada GDP Per Capita, 2019-2024, $
    • Table 79: Canada Population, 2019-2029, Millions
    • Table 80: Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 81: Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 82: Canada Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 83: South America GDP Per Capita, By Country, 2019-2024, $
    • Table 84:  South America Population, By Country, 2019-2029, Millions
    • Table 85: South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 86: South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 87: South America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 88: Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 89: Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 90: Brazil Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 91: Middle East GDP Per Capita, By Country, 2019-2024, $
    • Table 92:  Middle East Population, By Country, 2019-2029, Millions
    • Table 93: Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 94: Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 95: Middle East Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 96: Africa GDP Per Capita, By Country, 2018-2023, $
    • Table 97:  Africa Population, By Country, 2018-2028, Millions
    • Table 98: Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 99: Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 100: Africa Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Table 101: Global Primary Biliary Cholangitis Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)
    • Table 102: Intercept Pharmaceuticals Inc. – Financial Overview, 2019 – 2022, $ Billion
    • Table 103: Mayo Clinic Laboratories – Financial Overview, 2022-2023, $ Billion
    • Table 104: University of Pittsburgh Medical Center (UPMC) – Financial Overview, 2023, $ Billion
    • Table 105: Stanford Health Care – Financial Overview, 2019 – 2023, $ Billion
    • Table 106: Duke University Hospital – Financial Overview, 2019 – 2023, $Billion
    • Table 107: Primary Biliary Cholangitis Market, Competitive Benchmarking (In USD Millions)
    • Table 108: Primary Biliary Cholangitis Market, Competitive Dashboard
    • Table 109: Global Primary Biliary Cholangitis Market Size Gain ($ Million), 2024 – 2029, By Country
    • Table 110: Global Primary Biliary Cholangitis Market Size Gain ($ Million), Segmentation By Treatment Type, 2024 – 2029
    • Table 111: Global Primary Biliary Cholangitis Market Size Gain ($ Million), Segmentation By Diagnosis, 2024 – 2029
    • Table 112: Global Primary Biliary Cholangitis Market Size Gain ($ Million), Segmentation By End User, 2024 – 2029
    • Table 113: Primary Biliary Cholangitis Market Data Sources

    List Of Figures

      Figure 1: Global Primary Biliary Cholangitis Market Segmentation By Treatment Type
    • Figure 2: Global Primary Biliary Cholangitis Market Segmentation By Diagnosis
    • Figure 3: Global Primary Biliary Cholangitis Market Segmentation By End User
    • Figure 4: Global Primary Biliary Cholangitis Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
    • Figure 5: Global Primary Biliary Cholangitis Market, Historic, 2019 – 2024, $ Million
    • Figure 6: Global Primary Biliary Cholangitis Market, Forecast, 2024 – 2029, 2034F , $ Million
    • Figure 7: Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 8: Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 9: Global Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 10: Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 11: Global Primary Biliary Cholangitis Market, Sub-Segmentation By Liver Transplantation, By Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 12: Global Primary Biliary Cholangitis Market, By Region, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 13: Global Primary Biliary Cholangitis Market, By Country, Historic and Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 14: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 15: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 16: Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 17: China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 18: China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 19: China Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 20: India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 21: India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 22: India Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 23: Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 24: Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 25: Japan Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 26: Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 27: Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 28: Australia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 29: Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 30: Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 31: Indonesia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 32: South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 33: South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 34: South Korea Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 35: Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 36: Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 37: Western Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 38: UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 39: UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 40: UK Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 41: Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 42: Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 43: Germany Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 44: France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 45: France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 46: France Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 47: Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 48: Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 49: Italy Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 50: Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 51: Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 52: Spain Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 53: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 54: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 55: Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 56: Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 57: Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 58: Russia Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 59: North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 60: North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 61: North America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 62: USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 63: USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 64: USA Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 65: Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 66: Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 67: Canada Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 68: South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 69: South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 70: South America Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 71: Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 72: Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 73: Brazil Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 74: Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 75: Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 76: Middle East Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 77: Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 78: Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 79: Africa Primary Biliary Cholangitis Market, Segmentation By End User, Historic And Forecast, 2019 – 2024, 2029F, 2034F, $ Million
    • Figure 80: Global Primary Biliary Cholangitis Market, Key Competitor Estimated Market Shares, 2023, Percentage (%)
    • Figure 81: Intercept Pharmaceuticals Inc. – Financial Overview, 2019 – 2022, $ Billion
    • Figure 82: Stanford Health Care – Financial Overview, 2019 – 2023, $ Billion
    • Figure 83: BP – Financial Overview, 2019 – 2023, $ Billion
    • Figure 84: Geographic Regions Covered

    Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

    Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

    Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

    Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

    2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

    Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

    Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

    Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

    Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

    Read More About Anti-Inflammatory Biologics Market Revenue Outlook: Strategic Insights and Forecast to 2029

    CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

    Read More About CAGR of 10.8% Projected for Anti-Tumor Drugs Market From 2025 to 2029

    Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

    Read More About Future Demand and Leading Companies Shaping the Asthma Disease Market to 2029

    Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

    Read More About Comprehensive Forecast: Asthma Therapeutics Market Share, Growth, and Opportunities Through 2029

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By ...

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Ho...

    Pharmaceutical Drugs Market 2024 – By Type (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorde...

    Oncology Drugs Market 2023 – By Type (Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Tumor, Thyroid Cancer, Skin Cancer, Bladder Ca...

    Dry Eye Medication Market 2021 - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous And Evaporative) By Distribution Channel (Hospi...

    Oral Biologics & Biosimilar Drugs Market Report 2026 - Global Outlook – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, ...

    Monoclonal Antibodies (MAs) Market Report 2026 - Global Outlook – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacologic...

    Therapeutic Proteins Market Report 2026 - Global Outlook – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone), By Function (Enzymatic And Regulatory ...

    Back to top